{
    "nctId": "NCT02600442",
    "briefTitle": "Assessment of Breast Cancer Response to Neoadjuvant Anthracycline-based Chemotherapy by FDG-PET and Molecular Markers",
    "officialTitle": "Assessment of Breast Cancer Response to Neoadjuvant Anthracycline-based Chemotherapy by Fluorodeoxyglucose Positron Emission Tomography (FDG-PET) and Molecular Markers",
    "overallStatus": "UNKNOWN",
    "conditions": "Breast Neoplasms, Breast Cancer",
    "studyType": "OBSERVATIONAL",
    "phase": "N/A",
    "allocation": "N/A",
    "primaryPurpose": "N/A",
    "enrollmentCount": 168,
    "primaryOutcomeMeasure": "Pathological complete response to anthracycline-based neoadjuvant chemotherapy",
    "eligibilityCriteria": "Inclusion Criteria:\n\n* Women aged \u2265 18 years\n* Newly diagnosed invasive breast cancer\n* Stage-II or stage-III\n* Neoadjuvant anthracycline-based chemotherapy\n* Primary breast biopsy must be available\n* Non metastatic, M0\n* No prior systemic therapy for the presFrance: Direction Generale de la Sante ent tumor\n* Willingness and ability to comply with scheduled visits, treatment plan, laboratory tests, and other trial procedures\n\nExclusion Criteria:\n\n* Metastatic breast cancer\n* Uncontrolled diabetes\n* Limited breast cancer immediately accessible to conservative surgery and not candidate for neoadjuvant chemotherapy\n* Previous homolateral breast cancer and/or contralateral breast cancer except if treated by surgery +/- radiation therapy alone without any systemic treatment\n* Any surgery (not including minor procedures such as lymph node biopsy, primary tumor core biopsy, fine needle aspiration) within 12 weeks of start of study treatment; or not fully recovered from any side effects of previous procedures.\n* Diagnosis of any previous malignancy within the last 5 years, except for adequately treated basal cell carcinoma, or squamous cell skin carcinoma, or in situ cervical carcinoma",
    "sex": "ALL",
    "minimumAge": "N/A",
    "stdAges": "CHILD, ADULT, OLDER_ADULT"
}